Britain Courts Anthropic Amid US Defense Department Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
 Investors of September 12, 2016 Lead Plaintiff Deadline - EconoTimes)
SAN FRANCISCO, Sept. 07, 2016 -- Hagens Berman Sobol Shapiro LLP reminds investors in Juno Therapeutics Inc. (NASDAQ:JUNO) that the Lead Plaintiff Deadline is September 12, 2016.
If you purchased or otherwise acquired securities of Juno between June 4, 2016 and July 7, 2016 contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/JUNO
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
In May 2016, a Juno Therapeutics clinical trial patient died of a cerebral edema during Phase II testing of Juno’s JCAR015 drug (the “ROCKET Study”). The patient’s death was the result of a neurotoxicity side effect that company executives were allegedly aware of. The company failed to disclose the patient’s death and on June 4, 2016 touted that the ROCKET Study “Shows…Lower side effects.”
Six days after their positive ROCKET Study announcement, Juno’s Chief Executive Officer (Hans Bishop) and Chief Financial Officer (Steve Harr) began dumping Juno stock, selling approximately $10 million of Company shares in June 2016. The CEO’s June sales alone were more than twice the value of his total sales in 2015.
In July 2016, the FDA placed a clinical hold on the ROCKET Study due to the death of two more clinical trial patients. Juno disclosed the FDA hold, as well as the three clinical trial deaths, on July 7, 2016. In response, Juno’s stock price plummeted 31% to close at $27.81 per share on July 8, 2016.
“The timing of the May 2016 patient fatality, June 2016 '[l]ower side effects' announcement, and suspiciously-timed insider selling suggest Defendants’ knowledge of false or misleading statements and, in turn, securities law violations,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Juno Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
